Opposite Effect of Thyroid Hormones on Oxidative Stress and on Mitochondrial Respiration in COVID-19 Patients.
COVID-19
bioelectrical impedance analysis (BIA)
biological antioxidant potential (BAP)
extracellular flux analyzer
mitochondrial respiration
nonthyroidal illness syndrome (NTIS)
oxidative stress
reactive oxygen species (ROS)
thyroid hormones (THs)
Journal
Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981
Informations de publication
Date de publication:
08 Oct 2022
08 Oct 2022
Historique:
received:
20
08
2022
revised:
03
10
2022
accepted:
04
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Thyroid hormones (TH)s are master regulators of mitochondrial activity and biogenesis. Nonthyroidal illness syndrome (NTIS) is generally considered an adaptative response to reduced energy that is secondary to critical illness, including COVID-19. COVID-19 has been associated with profound changes in the cell energy metabolism, especially in the cells of the immune system, with a central role played by the mitochondria, considered the power units of every cell. Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects and alters mitochondrial functions, both to influence its intracellular survival and to evade host immunity. This study was undertaken to analyze the oxidative balance and mitochondrial respiration in COVID-19 patients with and without NTIS to elucidate the role that thyroid hormones (TH)s play in this context. In our cohort of 54 COVID-19 patients, admitted to our University Hospital during the COVID-19 pandemic, we evaluated the generation of reactive oxygen species (ROS) by measuring the serum levels of derivatives of reactive oxygen metabolites (dROMs), and we analyzed the antioxidant capacity by measuring the serum biological antioxidant potential (BAP). We then analyzed the mitochondrial respiration in peripheral blood mononuclear cells (PBMC)s of 28 of our COVID-19 patients, using the seahorse instrument (Agilent). Results were correlated with the serum levels of THs and, in particular, of FT3. In addition, the role of T3 on bioelectrical impedance analysis (BIA) and mitochondrial respiration parameters was directly evaluated in two COVID-19 patients with NTIS, in which treatment with synthetic liothyronine (LT3) was given both in vivo and in vitro. In our COVID-19 patients with NTIS, the dROMs values were significantly lower and the BAP values were significantly higher. Consequently, the oxidative stress index (OSi), measured as BAP/dROMs ratio was reduced compared to that observed in COVID-19 patients without NTIS, indicating a protective role exerted by NTIS on oxidative stress. In our COVID-19 patients, the mitochondrial respiration, measured in PBMCs, was reduced compared to healthy controls. Those with NTIS showed a reduced maximal respiratory capacity and a reduced proton leak, compared to those with normal FT3 serum values. Such lowered mitochondrial respiratory capacity makes the cells more vulnerable to bioenergetic exhaustion. In a pilot study involving two COVID-19 patients with NTIS, we could reinforce our previous observation regarding the role of T3 in the maintenance of adequate peripheral hydroelectrolytic balance. In addition, in these two patients, we demonstrated that by treating their PBMCs with LT3, both in vitro and in vivo, all mitochondrial respiration parameters significantly increased. Our results regarding the reduction in the serum levels of the reactive oxygen species (ROS) of COVID-19 patients with NTIS support the hypothesis that NTIS could represent an adaptative response to severe COVID-19. However, beside this beneficial effect, we demonstrate that, in the presence of an acute reduction of FT3 serum levels, the mitochondrial respiration is greatly impaired, with a consequent establishment of a hypoenergetic state of the immune cells that may hamper their capacity to react to massive viral infection.
Sections du résumé
BACKGROUND
BACKGROUND
Thyroid hormones (TH)s are master regulators of mitochondrial activity and biogenesis. Nonthyroidal illness syndrome (NTIS) is generally considered an adaptative response to reduced energy that is secondary to critical illness, including COVID-19. COVID-19 has been associated with profound changes in the cell energy metabolism, especially in the cells of the immune system, with a central role played by the mitochondria, considered the power units of every cell. Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects and alters mitochondrial functions, both to influence its intracellular survival and to evade host immunity.
AIM OF THE STUDY
OBJECTIVE
This study was undertaken to analyze the oxidative balance and mitochondrial respiration in COVID-19 patients with and without NTIS to elucidate the role that thyroid hormones (TH)s play in this context.
METHODS
METHODS
In our cohort of 54 COVID-19 patients, admitted to our University Hospital during the COVID-19 pandemic, we evaluated the generation of reactive oxygen species (ROS) by measuring the serum levels of derivatives of reactive oxygen metabolites (dROMs), and we analyzed the antioxidant capacity by measuring the serum biological antioxidant potential (BAP). We then analyzed the mitochondrial respiration in peripheral blood mononuclear cells (PBMC)s of 28 of our COVID-19 patients, using the seahorse instrument (Agilent). Results were correlated with the serum levels of THs and, in particular, of FT3. In addition, the role of T3 on bioelectrical impedance analysis (BIA) and mitochondrial respiration parameters was directly evaluated in two COVID-19 patients with NTIS, in which treatment with synthetic liothyronine (LT3) was given both in vivo and in vitro.
RESULTS
RESULTS
In our COVID-19 patients with NTIS, the dROMs values were significantly lower and the BAP values were significantly higher. Consequently, the oxidative stress index (OSi), measured as BAP/dROMs ratio was reduced compared to that observed in COVID-19 patients without NTIS, indicating a protective role exerted by NTIS on oxidative stress. In our COVID-19 patients, the mitochondrial respiration, measured in PBMCs, was reduced compared to healthy controls. Those with NTIS showed a reduced maximal respiratory capacity and a reduced proton leak, compared to those with normal FT3 serum values. Such lowered mitochondrial respiratory capacity makes the cells more vulnerable to bioenergetic exhaustion. In a pilot study involving two COVID-19 patients with NTIS, we could reinforce our previous observation regarding the role of T3 in the maintenance of adequate peripheral hydroelectrolytic balance. In addition, in these two patients, we demonstrated that by treating their PBMCs with LT3, both in vitro and in vivo, all mitochondrial respiration parameters significantly increased.
CONCLUSIONS
CONCLUSIONS
Our results regarding the reduction in the serum levels of the reactive oxygen species (ROS) of COVID-19 patients with NTIS support the hypothesis that NTIS could represent an adaptative response to severe COVID-19. However, beside this beneficial effect, we demonstrate that, in the presence of an acute reduction of FT3 serum levels, the mitochondrial respiration is greatly impaired, with a consequent establishment of a hypoenergetic state of the immune cells that may hamper their capacity to react to massive viral infection.
Identifiants
pubmed: 36290721
pii: antiox11101998
doi: 10.3390/antiox11101998
pmc: PMC9598114
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Sci (Lond). 2014 Sep;127(6):367-73
pubmed: 24895057
J Clin Med Res. 2016 Jun;8(6):437-44
pubmed: 27222671
Circ Res. 2015 Mar 13;116(6):1022-33
pubmed: 25767287
Nature. 2016 Jul 27;535(7613):551-5
pubmed: 27466127
Nat Med. 2018 Jan;24(1):39-49
pubmed: 29200204
Exp Gerontol. 2020 Dec;142:111147
pubmed: 33171276
Physiol Rev. 2014 Apr;94(2):355-82
pubmed: 24692351
J Endocr Soc. 2019 Oct 16;3(12):2313-2325
pubmed: 31745528
Cell Metab. 2016 Jun 14;23(6):1127-1139
pubmed: 27304511
Clin Obes. 2020 Dec;10(6):e12403
pubmed: 32857454
J Immunol. 2011 Sep 1;187(5):2559-68
pubmed: 21813773
Ann Endocrinol (Paris). 2007 Sep;68(4):224-8
pubmed: 17689479
Am J Physiol. 1995 Nov;269(5 Pt 2):R1213-24
pubmed: 7503313
Autophagy. 2019 Jan;15(1):131-150
pubmed: 30209975
PLoS One. 2017 Feb 8;12(2):e0170975
pubmed: 28178278
Eur J Endocrinol. 2009 Apr;160(4):503-15
pubmed: 19095779
Am J Physiol Cell Physiol. 2021 Jan 1;320(1):C57-C65
pubmed: 33151090
Cell. 2010 Mar 19;140(6):821-32
pubmed: 20303873
Physiol Res. 2019 Jun 30;68(3):347-363
pubmed: 30904011
Int J Environ Res Public Health. 2022 Jun 30;19(13):
pubmed: 35805716
Physiology (Bethesda). 2020 Sep 1;35(5):288-301
pubmed: 32783610
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Immun Ageing. 2020 Aug 24;17:23
pubmed: 32849908
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165838
pubmed: 32428560
Cell Tissue Res. 1984;236(2):321-5
pubmed: 6733758
Biogerontology. 2018 Dec;19(6):461-480
pubmed: 30143941
J Clin Endocrinol Metab. 1975 Jul;41(1):27-40
pubmed: 807593
Intensive Care Med. 2005 Oct;31(10):1356-61
pubmed: 16012806
Cureus. 2022 Apr 5;14(4):e23852
pubmed: 35530860
J Transl Med. 2021 Dec 3;19(1):491
pubmed: 34861865
iScience. 2020 Oct 23;23(10):101631
pubmed: 33015593
iScience. 2021 Dec 17;24(12):103471
pubmed: 34812416
Neuropharmacology. 2016 May;104:4-17
pubmed: 26056033
Chest. 2009 Jun;135(6):1448-1454
pubmed: 19255297
MAbs. 2015;7(1):199-211
pubmed: 25484043
Crit Care. 2011;15(1):R47
pubmed: 21291516
Thyroid. 2014 Dec;24(12):1670-751
pubmed: 25266247
Thyroid. 2008 Feb;18(2):145-56
pubmed: 18279015
Metabolism. 2007 Feb;56(2):239-44
pubmed: 17224339
Int J Cardiol. 2020 Aug 1;312:136
pubmed: 32505331
Clin Immunol. 2020 Oct;219:108544
pubmed: 32707089
Ann Rheum Dis. 2021 May;80(5):550-557
pubmed: 33293273
PLoS One. 2021 Mar 18;16(3):e0248771
pubmed: 33735311
J Endocrinol. 2017 Feb;232(2):R67-R81
pubmed: 27852725
Biomedicines. 2022 Jul 20;10(7):
pubmed: 35885051
Int J Mol Sci. 2020 Apr 24;21(8):
pubmed: 32344721
Am J Med. 1982 Jan;72(1):9-16
pubmed: 6800256
Trends Endocrinol Metab. 2021 Sep;32(9):659-671
pubmed: 34294513
EMBO Mol Med. 2020 Dec 7;12(12):e13001
pubmed: 33078545
Mediators Inflamm. 2016;2016:6757154
pubmed: 27051079
Clin Chem Lab Med. 2002 Nov;40(11):1132-4
pubmed: 12521231
Mol Immunol. 2018 Nov;103:115-124
pubmed: 30248487
J Clin Endocrinol Metab. 1997 Feb;82(2):329-34
pubmed: 9024211
Methods Enzymol. 2014;547:309-54
pubmed: 25416364
Front Physiol. 2015 Aug 21;6:237
pubmed: 26347660
Exp Gerontol. 2000 Sep;35(6-7):811-20
pubmed: 11053672
J Transl Med. 2021 Apr 1;19(1):139
pubmed: 33794925
Diabetes Metab Res Rev. 2020 Mar 31;:e33213321
pubmed: 32233018
Oxid Med Cell Longev. 2019 Aug 14;2019:3085756
pubmed: 31485289
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1133-1142
pubmed: 32663789
J Endocrinol. 2005 Apr;185(1):111-9
pubmed: 15817832
Cancer Res. 2019 May 1;79(9):2285-2297
pubmed: 30622116
J Endocrinol Invest. 2021 May;44(5):1031-1040
pubmed: 33140379
Am J Physiol Cell Physiol. 2020 Aug 1;319(2):C258-C267
pubmed: 32510973
Biol Psychiatry. 2018 May 1;83(9):722-730
pubmed: 29290371
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Nature. 2011 Jan 13;469(7329):221-5
pubmed: 21124315
Eur J Biochem. 1988 Dec 15;178(2):511-8
pubmed: 2850181
Front Endocrinol (Lausanne). 2022 May 10;13:850328
pubmed: 35620389
Acta Endocrinol (Copenh). 1980 Mar;93(3):322-31
pubmed: 6445670
Nat Rev Cardiol. 2020 Sep;17(9):543-558
pubmed: 32690910
Curr Opin Immunol. 2010 Feb;22(1):28-33
pubmed: 20060699
Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):E5679-88
pubmed: 26438848
Endocrinology. 2020 Oct 1;161(10):
pubmed: 32603424
Br J Anaesth. 2014 Dec;113(6):945-54
pubmed: 24970271